Globus Medical Inc. Class A Common Stock vs S&P Global Inc — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while S&P Global Inc trades at $411.5 (market cap $120.45B). The key difference: S&P Global Inc is far larger — about 11.8× Globus Medical Inc. Class A Common Stock's market cap, and S&P Global Inc pays a 0.95% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and S&P Global Inc for 124 Days on average.
| GMED | SPGI | |
|---|---|---|
Market Cap | $10.25B | $120.45B |
Volume | 1,059,528 | 1,198,667 |
Sector | Health | Financials |
52-Week High | $96.82 | $517.92 |
52-Week Low | $58.33 | $370.42 |
Typical Hold Time | 0 Days | 124 Days |
Enterprise Value | $9.76B | $131.93B |
Dividend Yield | — | 0.95% |
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
SPGI trades at $409.99, down 0.53% on the day, with a bullish technical signal despite mixed moving averages. The company reported strong revenue growth to $15.34 billion in 2025, with net income reaching $4.47 billion and a robust net margin of 30.54%. Recent developments include the acquisition of OpenZeppelin and the launch of new risk assessment services, expanding its market intelligence offerings.
The outlook remains positive with analyst consensus strongly bullish, an average price target of $509.50 implying significant upside. Risks include high valuation multiples and exposure to economic cycles, but sustained profitability and strategic expansions support long-term growth potential for investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →